Processa Pharmaceuticals's EBIT per Share for the
three
months ended in Dec. 2024 was $-0.78.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2024 was $-4.00.
During the past 3 years, the average EBIT per Share Growth Rate was 36.10% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 20.30% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 20.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Processa Pharmaceuticals's EBIT per Share or its related term are showing as below:
PCSA'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -30.4 Med: 28.15 Max: 77.7
Current: 36.1
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Processa Pharmaceuticals was 77.70% per year. The lowest was -30.40% per year. And the median was 28.15% per year.
PCSA's 3-Year EBIT Growth Rate is ranked better than 82.02% of 1235
companies
in the Biotechnology industry
Industry Median: 8
vs PCSA: 36.10
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.00
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Processa Pharmaceuticals (NAS:PCSA) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Processa Pharmaceuticals EBIT per Share Related Terms
Thank you for viewing the detailed overview of Processa Pharmaceuticals's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PCSA has been successfully added to your 